Skip to main content
. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2

ATI0918/NCT01715168.

Trial name or title A cross‐over bioequivalence study of intravenously administered ATI0918 and DOXIL/CAELYX in patients with ovarian cancer
Methods Phase I single‐blind RCT
Participants 40 women with ROC
Interventions PLD (50 mg/m²) versus ATI‐0918
Outcomes Pharmaco‐equivalence outcomes
Starting date Oct 2012
Contact information Karen Kuhn: kkuhn@ockham.com
Notes May 2013